Research progress on natural products in the treatment of autism spectrum disorder

doi:10.12092/j.issn.1009-2501.2026.05.015

Abstract

Abstract:

Autism spectrum disorder (ASD) is a neurodevelopmental disorder, and its core symptoms include deficits in social communication, repetitive and stereotyped behaviors, and narrow interests. Patients with ASD may have other psychiatric disorders such as attention deficit hyperactivity disorder, anxiety, irritability, sleep disturbances, and depression. At present, the clinical treatment drugs are mainly aimed at the comorbid psychiatric diseases of ASD, and the treatment needs to be vigilant against adverse reactions of ASD medicines, such as obesity, dyslipidemia, and diabetes mellitus, so a new treatment method is needed. In recent years, there have been ongoing clinical trials of alternative treatments using natural products. The results of the study have shown that some natural products have good effects in improving ASD symptoms, and natural products have broad prospects as a safe and effective ASD treatment strategy. This article reviews the natural products that have the potential to treat ASD, aiming to provide new ideas for the treatment of autism spectrum disorder.

Key words: autism spectrum disorder, natural products, treatment, neuroinflammation, oxidative stress

CLC Number:

R749.94

Qiankun DING, Dejie ZENG, Xiaqing SUN, Jili ZHAO, Qi SUN, Hongwei ZHU. Research progress on natural products in the treatment of autism spectrum disorder[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 700-708.

Figures/Tables 2

References 83

1	American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5 [M]. Arlington, VA: American Psychiatric Association, 2013.
2	Hirota T, King BH. Autism spectrum disorder: a review[J]. JAMA, 2023, 329 (2): 157- 168. doi: 10.1001/jama.2022.23661
3	Zeidan J, Fombonne E, Scorah J, et al. Global prevalence of autism: a systematic review update[J]. Autism Res, 2022, 15 (5): 778- 790. doi: 10.1002/aur.2696
4	Li Q, Li Y, Liu B, et al. Prevalence of autism spectrum disorder among children and adolescents in the United States From 2019 to 2020[J]. JAMA Pediatr, 2022, 176 (9): 943- 945. doi: 10.1001/jamapediatrics.2022.1846
5	Sacco R, Camilleri N, Eberhardt J, et al. A systematic review and meta-analysis on the prevalence of mental disorders among children and adolescents in Europe [J]. Eur Child Adolesc Psychiatry, 2022: 1-18.
6	Zhou H, Xu X, Yan W, et al. Prevalence of autism spectrum disorder in China: a nationwide multi-center population-based study among children aged 6 to 12 years[J]. Neurosci Bull, 2020, 36 (9): 961- 971. doi: 10.1007/s12264-020-00530-6
7	Hong M, Lee SM, Park S, et al. Prevalence and economic burden of autism spectrum disorder in South Korea using national health insurance data from 2008 to 2015[J]. J Autism Dev Disord, 2020, 50 (1): 333- 339. doi: 10.1007/s10803-019-04255-y
8	Sampaio F, Feldman I, Lavelle TA, et al. The cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic review[J]. Eur Child Adolesc Psychiatry, 2022, 31 (11): 1655- 1670. doi: 10.1007/s00787-021-01748-z
9	Rogge N, Janssen J. The economic costs of autism spectrum disorder: a literature review[J]. J Autism Dev Disord, 2019, 49 (7): 2873- 2900. doi: 10.1007/s10803-019-04014-z
10	Efstratopoulou M, Sofologi M, Giannoglou S, et al. Parental stress and Children's self-regulation problems in families with children with autism spectrum disorder (ASD)[J]. J Intell, 2022, 10 (1): 4. doi: 10.3390/jintelligence10010004
11	Waye MMY, Cheng HY. Genetics and epigenetics of autism: a review[J]. Psychiatry Clin Neurosci, 2018, 72 (4): 228- 244. doi: 10.1111/pcn.12606
12	D’Abate L, Walker S, Yuen RKC, et al. Predictive impact of rare genomic copy number variations in siblings of individuals with autism spectrum disorders[J]. Nat Commun, 2019, 10 (1): 5519. doi: 10.1038/s41467-019-13380-2
13	Hansen SN, Schendel DE, Francis RW, et al. Recurrence risk of autism in siblings and cousins: a multinational, population-based study[J]. J Am Acad Child Adolesc Psychiatry, 2019, 58 (9): 866- 875. doi: 10.1016/j.jaac.2018.11.017
14	Jiang CC, Lin LS, Long S, et al. Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications[J]. Signal Transduct Target Ther, 2022, 7 (1): 229. doi: 10.1038/s41392-022-01081-0
15	Zawadzka A, Cieślik M, Adamczyk A. The role of maternal immune activation in the pathogenesis of autism: a review of the evidence, proposed mechanisms and implications for treatment[J]. Int J Mol Sci, 2021, 22 (21): 11516. doi: 10.3390/ijms222111516
16	Usui N, Kobayashi H, Shimada S. Neuroinflammation and oxidative stress in the pathogenesis of autism spectrum disorder[J]. Int J Mol Sci, 2023, 24 (6): 5487. doi: 10.3390/ijms24065487
17	Han VX, Patel S, Jones HF, et al. Maternal acute and chronic inflammation in pregnancy is associated with common neurodevelopmental disorders: a systematic review[J]. Transl Psychiatry, 2021, 11 (1): 71. doi: 10.1038/s41398-021-01198-w
18	Liu X, Lin J, Zhang H, et al. Oxidative stress in autism spectrum disorder-current progress of mechanisms and biomarkers[J]. Front Psychiatry, 2022, 13, 813304.
19	Hollestein V, Poelmans G, Forde NJ, et al. Excitatory/inhibitory imbalance in autism: the role of glutamate and GABA gene-sets in symptoms and cortical brain structure[J]. Transl Psychiatry, 2023, 13 (1): 18. doi: 10.1038/s41398-023-02317-5
20	Nisar S, Bhat AA, Masoodi T, et al. Genetics of glutamate and its receptors in autism spectrum disorder[J]. Mol Psychiatry, 2022, 27 (5): 2380- 2392. doi: 10.1038/s41380-022-01506-w
21	Wang Q, Yang Q, Liu X. The microbiota-gut-brain axis and neurodevelopmental disorders[J]. Protein Cell, 2023, 14 (10): 762- 775.
22	Persico AM, Ricciardello A, Lamberti M, et al. The pediatric psychopharmacology of autism spectrum disorder: a systematic review - Part I: the past and the present[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2021, 110, 110326. doi: 10.1016/j.pnpbp.2021.110326
23	Eissa N, Al-Houqani M, Sadeq A, et al. Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder[J]. Front Neurosci, 2018, 12, 304. doi: 10.3389/fnins.2018.00304
24	Aishworiya R, Valica T, Hagerman R, et al. An update on psychopharmacological treatment of autism spectrum disorder[J]. Neurotherapeutics, 2022, 19 (1): 248- 262. doi: 10.1007/s13311-022-01183-1
25	Grosso C, Santos M, Barroso MF. From plants to psycho-neurology: unravelling the therapeutic benefits of bioactive compounds in brain disorders[J]. Antioxidants (Basel), 2023, 12 (8): 1603. doi: 10.3390/antiox12081603
26	Huang L, Kim MY, Cho JY. Immunopharmacological activities of luteolin in chronic diseases[J]. Int J Mol Sci, 2023, 24 (3): 2136. doi: 10.3390/ijms24032136
27	Zuiki M, Chiyonobu T, Yoshida M, et al. Luteolin attenuates interleukin-6-mediated astrogliosis in human iPSC-derived neural aggregates: a candidate preventive substance for maternal immune activation-induced abnormalities[J]. Neurosci Lett, 2017, 653, 296- 301. doi: 10.1016/j.neulet.2017.06.004
28	Millot P, San C, Bennana E, et al. STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation[J]. Immunol Lett, 2020, 228, 129- 134. doi: 10.1016/j.imlet.2020.10.004
29	Galvani G, Mottolese N, Gennaccaro L, et al. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder[J]. J Neuroinflammation, 2021, 18 (1): 155. doi: 10.1186/s12974-021-02204-0
30	Tassinari M, Mottolese N, Galvani G, et al. Luteolin treatment ameliorates brain development and behavioral performance in a mouse model of CDKL5 deficiency disorder[J]. Int J Mol Sci, 2022, 23 (15): 8719. doi: 10.3390/ijms23158719
31	Bertolino B, Crupi R, Impellizzeri D, et al. Beneficial effects of co-ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism[J]. CNS Neurosci Ther, 2017, 23 (1): 87- 98.
32	Theoharides TC, Asadi S, Panagiotidou S. A case series of a luteolin formulation (NeuroProtek®) in children with autism spectrum disorders[J]. Int J Immunopathol Pharmacol, 2012, 25 (2): 317- 323. doi: 10.1177/039463201202500201
33	Tsilioni I, Taliou A, Francis K, et al. Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6[J]. Transl Psychiatry, 2015, 5 (9): e647. doi: 10.1038/tp.2015.142
34	Akbarialiabad H, Dahroud MD, Khazaei MM, et al. Green tea, a medicinal food with promising neurological benefits[J]. Curr Neuropharmacol, 2021, 19 (3): 349- 359. doi: 10.2174/1570159X18666200529152625
35	Banji D, Banji OJ, Abbagoni S, et al. Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals[J]. Brain Res, 2011, 1410, 141- 151. doi: 10.1016/j.brainres.2011.06.063
36	Kumaravel P, Gabriel M, Vasanth N, et al. Epigallocatechin gallate attenuates behavioral defects in sodium valproate induced autism rat model[J]. Res J Pharm Technol, 2017, 10, 1477. doi: 10.5958/0974-360x.2017.00260.8
37	Haq IU, Imran M, Nadeem M, et al. Piperine: a review of its biological effects[J]. Phytother Res, 2021, 35 (2): 680- 700. doi: 10.1002/ptr.6855
38	Chen WS, An J, Li JJ, et al. Piperine attenuates lipopolysaccharide (LPS)-induced inflammatory responses in BV2 microglia[J]. Int Immunopharmacol, 2017, 42, 44- 48. doi: 10.1016/j.intimp.2016.11.001
39	Nasrnezhad R, Halalkhor S, Sadeghi F, et al. Piperine improves experimental autoimmune encephalomyelitis (EAE) in lewis rats through its neuroprotective, anti-inflammatory, and antioxidant effects[J]. Mol Neurobiol, 2021, 58 (11): 5473- 5493. doi: 10.1007/s12035-021-02497-5
40	Pragnya B, Kameshwari JS, Veeresh B. Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice[J]. Behav Brain Res, 2014, 270, 86- 94. doi: 10.1016/j.bbr.2014.04.045
41	Adami R, Bottai D. Curcumin and neurological diseases[J]. Nutr Neurosci, 2022, 25 (3): 441- 461. doi: 10.1080/1028415X.2020.1760531
42	Bhandari R, Kuhad A. Neuropsychopharmacotherapeutic efficacy of curcumin in experimental paradigm of autism spectrum disorders[J]. Life Sci, 2015, 141, 156- 169. doi: 10.1016/j.lfs.2015.09.012
43	Bassiouni W, Ali MAM, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease[J]. FEBS J, 2021, 288 (24): 7162- 7182. doi: 10.1111/febs.15701
44	Al-Askar M, Bhat RS, Selim M, et al. Postnatal treatment using curcumin supplements to amend the damage in VPA-induced rodent models of autism[J]. BMC Complement Altern Med, 2017, 17 (1): 259. doi: 10.1186/s12906-017-1763-7
45	Reshetnikov VV, Ayriyants KA, Ryabushkina YA, et al. Sex-specific behavioral and structural alterations caused by early-life stress in C57BL/6 and BTBR mice[J]. Behav Brain Res, 2021, 414, 113489. doi: 10.1016/j.bbr.2021.113489
46	Zhong H, Xiao R, Ruan R, et al. Neonatal curcumin treatment restores hippocampal neurogenesis and improves autism-related behaviors in a mouse model of autism[J]. Psychopharmacology (Berl), 2020, 237 (12): 3539- 3552. doi: 10.1007/s00213-020-05634-5
47	Jayaprakash P, Isaev D, Shabbir W, et al. Curcumin potentiates α7 nicotinic acetylcholine receptors and alleviates autistic-like social deficits and brain oxidative stress status in mice[J]. Int J Mol Sci, 2021, 22 (14): 7251. doi: 10.3390/ijms22147251
48	Rice LJ, Cannon L, Dadlani N, et al. Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review[J]. Eur Child Adolesc Psychiatry, 2024, 33 (2): 505- 526. doi: 10.1007/s00787-023-02169-w
49	Schultz S, Gould GG, Antonucci N, et al. Endocannabinoid system dysregulation from acetaminophen use may lead to autism spectrum disorder: Could cannabinoid treatment be efficacious[J]. Molecules, 2021, 26 (7): 1845. doi: 10.3390/molecules26071845
50	Zou M, Liu Y, Xie S, et al. Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder[J]. Open Biol, 2021, 11 (2): 200306. doi: 10.1098/rsob.200306
51	Siniscalco D, Sapone A, Giordano C, et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders[J]. Autism Dev Disord, 2013, 43 (11): 2686- 2695. doi: 10.1007/s10803-013-1824-9
52	Zamberletti E, Gabaglio M, Parolaro D. The endocannabinoid system and autism spectrum disorders: Insights from animal models[J]. Int J Mol Sci, 2017, 18 (9): 1916. doi: 10.3390/ijms18091916
53	Aran A, Harel M, Cassuto H, Polyansky L, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial[J]. Mol Autism, 2021, 12 (1): 6. doi: 10.1186/s13229-021-00420-2
54	Liu XG, Lu X, Gao W, et al. Structure, synthesis, biosynthesis, and activity of the characteristic compounds from Ginkgo biloba L[J]. Nat Prod Rep, 2022, 39 (3): 474- 511. doi: 10.1039/D1NP00026H
55	Gachowska M, Szlasa W, Saczko J, et al. Neuroregulatory role of ginkgolides[J]. Mol Biol Rep, 2021, 48 (7): 5689- 5697. doi: 10.1007/s11033-021-06535-2
56	Li X, Huang L, Liu G, et al. Ginkgo diterpene lactones inhibit cerebral ischemia/reperfusion induced inflammatory response in astrocytes via TLR4/NF-κB pathway in rats[J]. J Ethnopharmacol, 2020, 249, 112365. doi: 10.1016/j.jep.2019.112365
57	Ishola IO, Osele MO, Chijioke MC, et al. Isorhamnetin enhanced cortico-hippocampal learning and memory capability in mice with scopolamine-induced amnesia: Role of antioxidant defense, cholinergic and BDNF signaling[J]. Brain Res, 2019, 1712, 188- 196. doi: 10.1016/j.brainres.2019.02.017
58	Niederhofer H. First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder[J]. Phytother Res, 2009, 23 (11): 1645- 1646. doi: 10.1002/ptr.2778
59	Hasanzadeh E, Mohammadi MR, Ghanizadeh A, et al. A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders[J]. Child Psychiatry Hum Dev, 2012, 43 (5): 674- 682. doi: 10.1007/s10578-012-0292-3
60	Walker EA, Pellegrini MV. Bacopa monnieri [M]. Treasure Island (FL): StatPearls, 2023 Mar 17.
61	Shalini VT, Neelakanta SJ, Sriranjini JS. Neuroprotection with Bacopa monnieri-A review of experimental evidence[J]. Mol Biol Rep, 2021, 48 (3): 2653- 2668.
62	Abhishek M, Rubal S, Rohit K, et al. Neuroprotective effect of the standardised extract of Bacopa monnieri (BacoMind) in valproic acid model of autism spectrum disorder in rats[J]. J Ethnopharmacol, 2022, 293, 115199. doi: 10.1016/j.jep.2022.115199
63	Pham HTN, Tran HN, Nguyen PT, et al. Bacopa monnieri(L. ) Wettst. extract improves memory performance via promotion of neurogenesis in the hippocampal dentate gyrus of adolescent mice[J]. Int J Mol Sci, 2020, 21 (9): 3365.
64	Sivasangari K, Rajan KE. Standardized bacopa monnieri extract ameliorates learning and memory impairments through synaptic protein, neurogranin, pro-and mature BDNF signaling, and HPA axis in prenatally stressed rat offspring[J]. Antioxidants, 2020, 9 (12): 1229. doi: 10.3390/antiox9121229
65	Sathyanarayanan V, Thomas T, Einöther SJ, et al. Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults[J]. Psychopharmacology (Berl), 2013, 227 (2): 299- 306. doi: 10.1007/s00213-013-2978-z
66	Kumar N, Abichandani LG, Thawani V, et al. Efficacy of Standardized Extract of Bacopa monnieri (Bacognize®) on Cognitive Functions of Medical Students: A Six-Week, Randomized Placebo-Controlled Trial[J]. Evid Based Complement Alternat Med, 2016, 2016, 4103423.
67	Benmeziane-Derradji F. Evaluation of camel milk: gross composition-a scientific overview[J]. Trop Anim Health Prod, 2021, 53 (2): 308.
68	Al-Ayadhi LY, Elamin NE. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD)[J]. Evid Based Complement Alternat Med, 2013, 2013, 602834. doi: 10.1201/b18040-22
69	Hamzawy MA, El-Ghandour YB, Abdel-Aziem SH, et al. Leptin and camel milk abate oxidative stress status, genotoxicity induced in valproic acid rat model of autism [J]. Int J Immunopathol Pharmacol, 2018, 32: 2058738418785514.
70	Bashir S, Al-Ayadhi LY. Effect of camel milk on thymus and activation-regulated chemokine in autistic children: double-blind study[J]. Pediatr Res, 2014, 75 (4): 559- 563. doi: 10.1038/pr.2013.248
71	Shayganfard M. Molecular and biological functions of resveratrol in psychiatric disorders: a review of recent evidence[J]. Cell Biosci, 2020, 10 (1): 128. doi: 10.1186/s13578-020-00491-3
72	Menegas S, Keller GS, Possamai-Della T, et al. Potential mechanisms of action of resveratrol in prevention and therapy for mental disorders[J]. J Nutr Biochem, 2023, 121, 109435. doi: 10.1016/j.jnutbio.2023.109435
73	Shahrbabaki SSV, Moslemizadeh A, Amiresmaili S, et al. Ameliorating age-dependent effects of resveratrol on VPA-induced social impairments and anxiety-like behaviors in a rat model of neurodevelopmental disorder[J]. Neurotoxicology, 2023, 96, 154- 165. doi: 10.1016/j.neuro.2023.03.003
74	Hidema S, Kikuchi S, Takata R, et al. Single administration of resveratrol improves social behavior in adult mouse models of autism spectrum disorder[J]. Biosci Biotechnol Biochem, 2020, 84 (11): 2207- 2214. doi: 10.1080/09168451.2020.1794783
75	Juybari KB, Sepehri G, Meymandi MS, et al. Sex dependent alterations of resveratrol on social behaviors and nociceptive reactivity in VPA-induced autistic-like model in rats[J]. Neurotoxicol Teratol, 2020, 81, 106905. doi: 10.1016/j.ntt.2020.106905
76	Marchezan J, Deckmann I, da Fonseca GC, et al. Resveratrol treatment of autism spectrum disorder-A pilot study[J]. Clin Neuropharmacol, 2022, 45 (5): 122- 127.
77	Hendouei F, Sanjari Moghaddam H, Mohammadi MR, et al. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double-blind and placebo-controlled randomized trial[J]. J Clin Pharm Ther, 2020, 45 (2): 324- 334.
78	Zhao T, Yang M, Ma L, et al. Structural modification and biological activity of polysaccharides[J]. Molecules, 2023, 28 (14): 5416. doi: 10.3390/molecules28145416
79	Zhao Y, Yan B, Wang Z, et al. Natural polysaccharides with immunomodulatory activities[J]. Mini Rev Med Chem, 2020, 20 (2): 96- 106. doi: 10.2174/1389557519666190913151632
80	Yang X, Li J, Zhou Y, et al. Effect of stigma maydis polysaccharide on the gut microbiota and transcriptome of VPA induced autism model rats[J]. Front Microbiol, 2022, 13, 1009502. doi: 10.3389/fmicb.2022.1009502
81	Raghavan K, Dedeepiya VD, Kandaswamy RS, et al. Improvement of sleep and melatonin in children with autism spectrum disorder after β-1, 3/1, 6-glucan consumption: An open-label prospective pilot clinical study[J]. Brain Behav, 2022, 12 (9): e2750.
82	Raghavan K, Dedeepiya VD, Yamamoto N, et al. Benefits of gut microbiota reconstitution by beta 1, 3-1, 6 glucans in subjects with autism spectrum disorder and other neurodegenerative diseases[J]. J Alzheimers Dis, 2023, 94 (s1): S241- S252. doi: 10.3233/JAD-220388
83	Wang Y, Li N, Yang JJ, et al. Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder[J]. Pharmacol Res, 2020, 157, 104784. doi: 10.1016/j.phrs.2020.104784

天然产物	主要作用机制	实验对象	结论	发表日期
木犀草素	抗炎抗氧化抗凋亡	Cdkl5 KO 小鼠	行为改善，促进脑皮质神经元成熟和海马神经元可塑性。	2022^[30]
		ASD小鼠	行为改善，炎症水平下降，抑制细胞凋亡和增加神经元细胞可塑性。	2017^[31]
		ASD儿童	问卷评分降低，行为改善。	2017^[31]
		ASD儿童	行为改善。	2012^[32]
		ASD儿童	行为改善，炎症水平下降。	2015^[33]
绿茶提取物	抗氧化抗凋亡	ASD小鼠	行为改善，脂质过氧化水平降低，保护浦肯野细胞。	2011^[35]
绿茶提取物	抗氧化抗凋亡	ASD大鼠	行为改善。	2017^[36]
胡椒碱	抗氧化抗凋亡	ASD小鼠	行为改善，氧化应激水平下降，保护浦肯野细胞。	2014^[40]
姜黄素	抗炎抗氧化抗凋亡	ASD大鼠	行为改善，氧化应激水平下降。	2015^[42]
		ASD大鼠	氧化应激水平下降。	2017^[44]
		BTBRT小鼠	行为改善，促进神经干细胞增殖。	2020^[46]
		BTBRT小鼠	行为改善，氧化应激水平下降。	2021^[47]
大麻素	抗氧化调节神经递质	ASD大鼠	行为改善，氧化应激水平下降。	2021^[50]
大麻素	抗氧化调节神经递质	ASD儿童	破环行为改善。	2021^[50]
银杏提取物	抗炎抗氧化	ASD儿童	部分行为改善。	2009^[58]
银杏提取物	抗炎抗氧化	ASD儿童	联合利培酮治疗较利培酮单独治疗无明显改善。	2012^[59]
假马齿苋	抗炎抗氧化抗凋亡	ASD大鼠	行为改善，炎症水平和氧化应激水平下降。	2022^[62]
		成人	缓解焦虑、改善认知。	2013^[65]
		成人	增强认知功能。	2016^[66]
骆驼奶	抗炎抗氧化	ASD大鼠	炎症水平下降，抗氧化酶活性增加。	2018^[69]
		ASD儿童	问卷评分降低，血清活化调节趋化因子水平降低。	2013^[68]
		ASD儿童	问卷评分降低，抗氧化水平增加。	2014^[70]
白藜芦醇	抗炎抗氧化	ASD大鼠	行为改善。	2023^[73]
		ASD儿童	问卷评分降低，易激惹症状改善。	2022^[76]
		ASD儿童	多动和依从性改善	2020^[77]
生物多糖	调节代谢调节肠道菌群	ASD大鼠	大鼠行为改善，肠道菌群改变。	2022^[80]
		ASD儿童	行为改善，肠道菌群重建。	2023^[81]
		ASD儿童	行为改善，多巴胺能水平升高，肠道菌群重建。	2020^[83]

天然产物	主要作用机制	实验对象	结论	发表日期
木犀草素	抗炎抗氧化抗凋亡	Cdkl5 KO 小鼠	行为改善，促进脑皮质神经元成熟和海马神经元可塑性。	2022^[30]
		ASD小鼠	行为改善，炎症水平下降，抑制细胞凋亡和增加神经元细胞可塑性。	2017^[31]
		ASD儿童	问卷评分降低，行为改善。	2017^[31]
		ASD儿童	行为改善。	2012^[32]
		ASD儿童	行为改善，炎症水平下降。	2015^[33]
绿茶提取物	抗氧化抗凋亡	ASD小鼠	行为改善，脂质过氧化水平降低，保护浦肯野细胞。	2011^[35]
绿茶提取物	抗氧化抗凋亡	ASD大鼠	行为改善。	2017^[36]
胡椒碱	抗氧化抗凋亡	ASD小鼠	行为改善，氧化应激水平下降，保护浦肯野细胞。	2014^[40]
姜黄素	抗炎抗氧化抗凋亡	ASD大鼠	行为改善，氧化应激水平下降。	2015^[42]
		ASD大鼠	氧化应激水平下降。	2017^[44]
		BTBRT小鼠	行为改善，促进神经干细胞增殖。	2020^[46]
		BTBRT小鼠	行为改善，氧化应激水平下降。	2021^[47]
大麻素	抗氧化调节神经递质	ASD大鼠	行为改善，氧化应激水平下降。	2021^[50]
大麻素	抗氧化调节神经递质	ASD儿童	破环行为改善。	2021^[50]
银杏提取物	抗炎抗氧化	ASD儿童	部分行为改善。	2009^[58]
银杏提取物	抗炎抗氧化	ASD儿童	联合利培酮治疗较利培酮单独治疗无明显改善。	2012^[59]
假马齿苋	抗炎抗氧化抗凋亡	ASD大鼠	行为改善，炎症水平和氧化应激水平下降。	2022^[62]
		成人	缓解焦虑、改善认知。	2013^[65]
		成人	增强认知功能。	2016^[66]
骆驼奶	抗炎抗氧化	ASD大鼠	炎症水平下降，抗氧化酶活性增加。	2018^[69]
		ASD儿童	问卷评分降低，血清活化调节趋化因子水平降低。	2013^[68]
		ASD儿童	问卷评分降低，抗氧化水平增加。	2014^[70]
白藜芦醇	抗炎抗氧化	ASD大鼠	行为改善。	2023^[73]
		ASD儿童	问卷评分降低，易激惹症状改善。	2022^[76]
		ASD儿童	多动和依从性改善	2020^[77]
生物多糖	调节代谢调节肠道菌群	ASD大鼠	大鼠行为改善，肠道菌群改变。	2022^[80]
		ASD儿童	行为改善，肠道菌群重建。	2023^[81]
		ASD儿童	行为改善，多巴胺能水平升高，肠道菌群重建。	2020^[83]

[1]	Mina GAO, Liya YANG, Shangying DUAN, Xinlu CHEN, Xiaoya LI, Bo QIAO, Yueying WU. Research progress on the prevention and treatment of high-altitude diseases by traditional Chinese medicine based on the "lung-brain axis" [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 675-682.
[2]	Kang ZENG, Weixin XING, Qingchun MU. Research progress of patchouli alcohol in the treatment of ischemia-related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 691-699.
[3]	Qun ZHANG, Hui SHI, Lingling DAI, Jingjing GAO. Research progress on the mechanism of vitamin D expression in the pathogenesis of endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 716-720.
[4]	Jieyu ZHANG, Yina WENG, Fei CAO. microRNAs expression profile changes in patients with Parkinson's disease and prospects for potential diagnosis and treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 551-560.
[5]	Jiawei ZHANG, Xuehan MA, Enhao XIAO, Simiao FAN, Danyang LIU. Uridine cytidine kinase 2's function in tumors and the ongoing research on its inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 362-371.
[6]	Weichen WANG, Yaping MA, Meng WANG, Qinglin LI, Hui CHENG. Therapeutic effect of emodin on cholestatic liver injury in mice based on CYP7A1 / FXR / SHP pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 204-212.
[7]	Qing ZHANG, Panwei HU, Hua ZHOU. Animal model of intrauterine adhesions and its application in the treatment of intrauterine adhesions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 257-264.
[8]	YANG Huanran, WU Shengnan, GAO Qin. Dexmedetomidine alleviates ferroptosis in rat cerebral ischemia/reperfusion injury by inhibiting the Nrf2 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 921-928.
[9]	YANG Dongli, LI Jing, DUAN Lifang, ZHANG Wenjiang, LI Na, ZHANG Hong. Advances in the anti-fibrosis effect of oxidative stress-related regulatory protein Cygb [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(5): 683-689.
[10]	XU Tingting, WANG Wanjie, BAO Jing, XIA Ruixiang. The relationship between NLRC4-mediated inflammasome pathway and multiple myeloma and its therapeutic prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 501-508.
[11]	CHU Yunqian, XUE Ya, JIANG Hua, QI Chunjian, DAI Hanjue, XIAN Qingying, ZHU Wenyu. Exploratory study of fecal microbiota transplantation combined with immune checkpoint inhibitors in the treatment of end-stage malignant tumor patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 509-516.
[12]	LU Qi, DU Lili, SUN Jin. The role of platelets in tumor development and the treatments based on them [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 290-296.
[13]	CHEN Zhenmei, CHEN Jinhong. Advances in precision diagnosis and treatment of cholangiocarcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 159-170.
[14]	YU Xiaohai, JIN Yu, SUN Minqiong, CONG Hui, GUO Qianying. Ameliorating effect of total flavonoids of rhododendron on brain oxidative stress injury in cerebral ischemia-reperfusion rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 216-221.
[15]	LI Qingyun, HUANG Ke. Etiology, diagnosis, and current treatment of excessive daytime sleepiness [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(12): 1587-1595.